On May 12, Yuyue Medical 2021 New Product Launch Conference was held in Shanghai. At the meeting, Wu Qun, chairman of Yuyue Medical, released a new strategy - innovation to reshape medical devices.
He pointed out that in the future, Yuyue will focus on three core tracks on the cornerstone businesses such as blood pressure monitoring, body temperature monitoring, traditional Chinese medicine equipment, and surgical instruments: breathing, POCT (instant detection), infection control, and will continue to incubate high-potential businesses such as first aid, ophthalmology, and intelligent rehabilitation.
After the meeting, in an interview with the Observer Network, Wu Qun mentioned that the future mergers and acquisitions and transformation of Yuyue Medical will focus more on the above core tracks, and find and acquire excellent targets on the core tracks on a global scale.
Yuyue Medical released a total of four new products at this conference, namely continuous glucose monitoring system, portable oxygen concentrator, household high-flow respiratory humidification treatment instrument, automatic external defibrillator, etc.
The Continuous Glucose Monitoring System "Amanosaccharide Anytime" is a CGM product (Continuous Glucose Monitoring) launched by Yuyue Medical and Kate.
The product can meet the clinical needs of patients' blood glucose management, and can be combined with Yuyue's existing blood glucose business to create a comprehensive clinical solution of finger blood test + continuous glucose monitoring.
It is worth mentioning that on the evening of May 10, Yuyue Medical announced that it intends to transfer 50.993% of the equity of Kailite held by a total of 7 parties, including Kailian Medical, a shareholder of Kailite.
The former is required to pay $366 million to each transferor and to inherit the 42 million capital contribution obligations under the previous round of financing agreements that the relevant transferors have not fulfilled.
In an interview with the Observer Network, Wu Qun said that the company will continue to lay out and find relevant target companies on the three core tracks of breathing, POCT and infection control.
"On the one hand, based on our ability, we can carry these acquired companies, on the other hand, we can also empower these enterprises." he said.
It is not difficult to see that the acquisition of Kailite by Yuyue Medical is a new strategic layout of its three main tracks of breathing, POCT and infection control.
At the meeting, Yuyue Medical also released the portable oxygen concentrator Spirit-3. The portable oxygen concentrator weighing only 2.2kg adopts the first replacement portable molecular sieve in China, which stabilizes oxygen and can be used continuously at an altitude of 0-5000m.
Also released was the HF-60M household high-flow respiratory humidification therapy. The product is equipped with a 7-inch touch screen, real-time monitoring of many parameters such as blood oxygen and pulse rate, a number of alarms, gas circuit separation design, precise temperature control, and comprehensive upgrade of experience, suitable for nearly 20 kinds of acute and chronic respiratory diseases.
In addition, AED, a life-saving artifact under Yuyue Medical, launched a new model. The automatic external defibrillator M600 charging speed ≤ 5 seconds, setting a new record in the industry, CPR feedback, child mode, professional improvement of treatment rate, The Internet of Things data center fully integrates emergency resources.
At the meeting, Wu Qun promised that in the future, Yuyue Medical's annual R&D investment will not be less than 8% of sales.
In 2020, Yuyue Medical's R&D expenses were close to 402 million yuan, an increase of 70.81% year-on-year, and the capitalization of R&D investment accounted for 0%, accounting for 5.97% of the annual revenue.
In this regard, industry insiders said that Yuyue has long paid attention to independent research and development. In the future, Yuyue is expected to further lead the development of the industry and enhance the global competitiveness of Chinese brands under the background of medical device import substitution, grassroots market expansion, and rapid development of private hospitals.